Anumana, a health technology company focused on artificial intelligence (AI) applications in cardiology, has expanded the scope of its ECG-AI platform to address the full continuum of cardiovascular care.
The announcement follows the inclusion of Boston Scientific as a new investor in Anumana’s Series C financing round. The funding will support the company’s transition from diagnostic AI solutions to applications in perioperative and acute cardiac care, along with further development of Software as a Medical Device (SaMD).
The new capital is expected to advance Anumana’s suite of multimodal generative AI solutions, enabling integration into clinical workflows that span preventive screening to interventional cardiology. The investment reinforces the company’s strategy to scale its ECG-AI technology beyond outpatient diagnostics into hospital and surgical settings.
Anumana plans to use the proceeds to support regulatory progress and commercial adoption of its ECG-AI algorithms, particularly in primary care and outpatient contexts.
The company will also use the investment to generate clinical evidence on the utility of AI-based ECG tools in early detection and treatment planning, positioning ECG-AI technology as a standard component of preventive cardiology.
Anumana CEO Maulik Nanavaty said: “This new investment is a strong validation of Anumana’s strategic direction and momentum.
“We’ve built a solid foundation in diagnostic cardiology AI, and we’re now extending that expertise into the perioperative setting. By applying generative AI to imaging and intraoperative support, we’re creating intuitive offerings to interpret complex data in real time and facilitate delivery of care.”
As part of its expansion into perioperative settings, Anumana is developing real-time imaging systems and predictive AI models intended to support intraoperative decision-making in cardiac procedures. These offerings will initially focus on structural heart, electrophysiology, and interventional cardiology domains.
The company aims to integrate these tools directly into surgical environments to improve precision during interventions.
Anumana will work in partnership with Boston Scientific to develop AI-based support systems for electrophysiology procedures, including cardiac ablation and left atrial appendage closure for the treatment of atrial fibrillation. The companies are focusing on solutions that integrate seamlessly with clinical workflows and provide data-driven decision support during surgery.
The company’s multimodal AI solutions are powered by nference’s data analytics platform, which utilises de-identified longitudinal patient records across millions of individuals. These capabilities enable the development of AI tools that offer earlier diagnosis and improved workflow efficiency, with the potential to shift clinical practice standards in cardiac care.
Anumana’s Series C round also had participation from existing investors including Matrix Capital, Matrix Partners, Mayo Clinic, and NTTVC.
Earlier this year, Anumana entered into a collaboration with AliveCor to bring its ECG-AI algorithms to consumer and clinical-grade electrocardiogram (ECG) devices.
The partnership focuses on deploying the FDA-cleared ECG-AI LEF algorithm on AliveCor’s Kardia systems, including the Kardia 12L ECG System, to detect low ejection fraction (LEF), a key indicator of heart failure. This initiative aims to enable earlier identification of cardiovascular disease by using routine 12-lead ECG data, potentially accelerating clinical intervention pathways.
Anumana’s ECG-AI platform encompasses a portfolio of algorithms designed to identify cardiac conditions that are otherwise difficult to detect without specialised tests.
